Resource Library

This white paper presents a head-to-head validation dataset showing that an engineered E. coli cell-free protein synthesis (CFPS) system produces full-length IgG1 antibodies whose early binding readouts closely track CHO-made controls. The goal isn’t to replace CHO — it’s to establish CFPS as a reliable triage step before every candidate is committed to mammalian expression,…

Validating thousands of AI-generated antibody variants in slow mammalian workflows creates a massive bottleneck. This white paper introduces an automated, 96-plex cell-free protein synthesis (CFPS) triage step prior to CHO scale-up. A 14-day sequence-to-decision workflow achieved 99% full-length IgG expression across 188 AI variants and successfully diverted 139 non-binders from costly validation. Delivering up to…

Relying on slow, capacity-limited mammalian expression to assess hundreds of antibody sequences creates a 4-to-5-week validation bottleneck. This featured poster introduces an engineered E. coli cell-free protein synthesis (CFPS) workflow to rapidly triage out non-binders before committing to costly biology. The system successfully produces full-length, fully assembled antibodies with proper disulfide bonds at screening-relevant yields.…

AI models are generating thousands of promising antibody variants faster than ever before. But because downstream mammalian expression and SPR validation are high-cost and time-consuming, teams are forced into a costly bottleneck—often over-investing in candidates that simply do not bind. Join Stacey Willard, Vice President of Marketing and Product Management at Nuclera, for insights into…

Join Dr. Magdalena Richter, Associate Principal Scientist at AstraZeneca, as she details how her team systematically addressed this bottleneck. By benchmarking Nuclera’s eProtein Discovery™ system against standard E. coli cell-based expression, her team asked a critical question: Can a 24-hour, cell-free screen accurately predict expression success at scale?

The missing triage step for AI antibody discovery. Download our flyer to discover how Nuclera filters out non-binders before high-cost downstream validation. Learn how our 96-plex full-length IgG binary cell-free expression and binding screen is combined with focused SPR to help you confidently eliminate bad candidates early. Shrink your list without adding CapEx or headcount,…

An overview of eProtein Discovery™ a rapid protein access system located on your benchtop, which enables you to go from DNA to protein in less than 48 hours.

Stop wasting weeks on empirical GPCR detergent screening. This application note demonstrates a rapid, automated cell-free workflow that inserts the β1-adrenergic receptor (β1AR) directly into defined nanodiscs. Using eProtein Discovery™ multiplex screening, researchers can pinpoint optimal lipid environments in 24 hours, scale up to ~100 µg/mL yields, and isolate highly pure, structure-ready GPCRs in less…

This talk delves into recent innovations Bayer Crops have adapted using Nuclera’s eProtein Discovery™ system that is transforming the landscape of membrane protein purification. Dr. Wenguang Liang will discuss high-throughput screening methods that expedite optimization processes, followed by advanced expression systems and novel extraction techniques that enhance both yield and stability.

Join Dr. Tobias Ost, SVP of Product Development at Nuclera, as we unveil our new, expertly curated eProtein Discovery™ GPCR Nanodiscs. Discover how combining cell-free protein synthesis with co-translational insertion directly into pre-assembled nanodiscs stabilizes GPCRs as they are synthesized. Dr. Ost will demonstrate how the eProtein Discovery™ system automates multiplex screening of GPCR constructs…